Abbott Laboratories

New York Stock Exchange
Back to all articles
Bullish +62

Abbott Laboratories stock gains on USD 385 million infant formula settlement and solid July earnings

AI-generated analysis

📈 Abbott Laboratories stock traded at USD 102.35 on September 19, 2026, supported by reduced legal risk from a nearly USD 385 million infant formula settlement.

💰 The company reported June-quarter revenue of USD 12.59 billion, up 13.0 percent year over year, with adjusted EPS of USD 1.31 beating consensus.

🤝 Abbott agreed to pay about USD 348.7 million to the federal government and more than USD 35 million to states to resolve claims over powdered infant formula manufacturing issues.

📊 Wall Street's average price target stands at USD 119.50, above the latest quoted share price, indicating a bullish analyst stance.

🚀 Regulatory approval for the TactiFlex Duo ablation catheter adds to Abbott's cardiovascular portfolio and could support long-term revenue growth.

📅 The next scheduled earnings report is expected on October 16, 2026, serving as a key checkpoint for investors.

🏛️ New York alone is expected to receive more than USD 9.3 million from the settlement proceeds, with around USD 5.3 million earmarked for Medicaid.

📉 Profit margin for 2026 is projected at roughly 11.64 percent, with investors monitoring potential compression risks alongside the settlement impact.

🔍 The settlement resolves a broad set of federal and state claims, closing key investigations into manufacturing issues without an admission of liability.

Bullish Signals
  • Abbott Laboratories stock gained value as a nearly USD 385 million infant formula settlement reduced significant legal uncertainty and resolved broad federal and state claims.
  • The company delivered strong June-quarter revenue of USD 12.59 billion, representing a 13.0 percent year-over-year increase while beating EPS consensus estimates.
  • Management maintained full-year 2026 guidance of USD 5.45 to USD 5.60 in adjusted EPS, signaling confidence in earnings resilience despite litigation costs.
  • Wall Street's average price target stands at USD 119.50, above the current share price, with recent upgrades from BTIG Research and Wolfe Research reinforcing a bullish stance.
  • Regulatory approval for the TactiFlex Duo ablation catheter adds to Abbott's cardiovascular portfolio, offering potential for long-term revenue growth.
Risk Factors
  • Investors face risks including margin compression, with profit margin for 2026 projected at roughly 11.64 percent.
  • The financial impact of the roughly USD 385 million infant formula settlement weighs on earnings quality and represents a significant cash outflow.
  • While Wall Street remains largely bullish, the company must balance growth initiatives with the ongoing financial clean-up from the infant formula episode.
Full Analysis
Abbott Laboratories stock gained value on September 19, 2026, trading at USD 102.35 following a significant reduction in legal uncertainty regarding its infant formula business. The company agreed to a settlement of nearly USD 385 million related to a 2022 recall and plant shutdown, resolving broad federal and state claims without admitting liability. This financial clean-up effectively removes a major overhang from the stock's valuation. Financial performance for the quarter ended June 2026 was robust, with revenue reaching USD 12.59 billion, representing a 13.0 percent year-over-year increase. Adjusted earnings per share grew to USD 1.31, surpassing analyst consensus estimates despite ongoing litigation costs. Management maintained full-year 2026 guidance of USD 5.45 to USD 5.60 in adjusted EPS, signaling confidence in earnings resilience. Analyst sentiment remains broadly positive, with a Wall Street average price target of USD 119.50 above the current share price. Recent upgrades from BTIG Research and Wolfe Research reinforce this bullish stance. While investors monitor risks such as margin compression and the financial impact of the settlement, product developments like the TactiFlex Duo ablation catheter offer long-term growth potential in the cardiovascular portfolio. The company is positioned for continued scrutiny ahead of its next earnings report scheduled for October 16, 2026. With a market capitalization of USD 177.11 billion, Abbott balances the immediate financial impact of the settlement against its strong operational growth and strategic product approvals, maintaining a solid investment case within its current trading range.